Homoharringtonine-induced hyperglycemia.
Homoharringtonine (HHT) has been reported to induce hyperglycemia. This report describes a study conducted to characterize the effect of HHT on insulin production and action. Our data indicate that HHT-induced hyperglycemia results from the development of insulin resistance. A review of the literature suggests that patients receiving HHT continuous infusions of 5 mg/m2/d or greater and patients greater than 10 years of age may be at increased risk for the development of HHT-induced hyperglycemia. We recommend that patients with these risk factors, as well as diabetic patients and patients concurrently receiving asparaginase and/or prednisone, have their blood glucoses routinely monitored for hyperglycemia.
Sylvester
R K
RK
Department of Pharmacy, United Hospital, St. Paul, MN 55102.
Lobell
M
M
Ogden
W
W
Stewart
J A
JA
D000208:Acute Disease; D000470:Alkaloids / Q000009:adverse effects*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000652:urine; D004341:Drug Evaluation; D006248:Harringtonines / Q000008:administration & dosage / Q000009:adverse effects*; D000077863:Homoharringtonine; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000378:metabolism; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D007938:Leukemia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D012307:Risk Factors; D013997:Time Factors
D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D001786:Blood Glucose; D002096:C-Peptide; D006248:Harringtonines; D007328:Insulin; D000077863:Homoharringtonine